Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
h1 virus-like particle influenza vaccine
- Development stage
- Unknown
- Lead developer
- Novavax
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **h1 virus-like particle influenza vaccine** is a vaccine candidate that uses **virus-like particles (VLPs)** engineered to display the hemagglutinin (HA) and neuraminidase (NA) proteins of an H1 subtype influenza A virus. VLPs mimic the structure of native influenza virions but lack viral genomic RNA, making them non-infectious while still immunogenic. This modality can induce both humoral and cellular immune responses, including the generation of neutralizing antibodies against H1-HA and NA, as well as robust T-cell responses. VLP-based vaccines are under clinical investigation for their potential to yield broader and more durable immunity compared to traditional inactivated or split-virion influenza vaccines. They may also be formulated as bivalent or multivalent vaccines by combining VLPs representing multiple influenza subtypes.
- Other names
- H1 VLP influenza vaccineH-1 VLP influenza vaccineH 1 VLP influenza vaccineH1N1 VLP influenza vaccineH-1N1 VLP influenza vaccineH 1N1 VLP influenza vaccineInfluenza A H1N1 VLP vaccine
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on h1 virus-like particle influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on h1 virus-like particle influenza vaccine.